New social contract beckons for investors in pharma
“Shared Value: Rebuilding Pharma’s Contract with Society” is the fourth report published by the PharmaFutures project involving institutional investors and pharmaceutical companies.
The report suggests that there is a growing gap between end patient demands, what level of consumption of pharmaceutical products that societies are willing to pay for, and concerns among investors about the level of return they may get from investing in the industry.
Among the key recommendations made by the report are:
– Healthcare providers to send clearer signals about priority focus for treatments
– Investors need to continue the critical role of funding new drug discovery
– Investors need to be prepared to support new models of sharing R&D risk
– Investors need to consider taking a more activist role
– Investors should consider a focus on long term return from R&D
PharmaFutures director, Sophia Tickell said: “The industry’s social contract is under severe strain. There is an urgent need for new treatments for antibiotics and diseases like Alzheimer’s. It is in the interest of patients, healthcare providers, industry and pension holders to work together to create the best model for bringing new drugs to market.”
The PharmaFutures project was founded in 2003. Investors participating in the latest, fourth, report included APG, Carson Capital, Fidelity, Robeco, TIAA-CREF and the UK’s Universities Superannuation Scheme. Together they represent about £1.7trn in assets under management.
Pharmaceutical companies participating included Amgen, GSK, Johnson & Johnson, Novo Nordisk and Shire.
Click here to read a full copy Shared Value: Rebuilding Pharma’s Contract with Society